-transparent.png){kind=logo}
A murine plasmacytoma MOPC 104E (MOPC) is highly sensitive to chemotherapeutic agents such as cyclophosphamide and mitomycin C as well as to immunotherapy (OK-432-combined adoptive immunotherapy using interleukin-2-cultured killer cells). In the present study, we prepared cyclophosphamide-resistant MOPC cells (MOPC-CPA/R) by serial in vivo passage of tumor cells following cyclophosphamide treatment. The in vivo sensitivity of MOPC-CPA/R to mitomycin C or to immunotherapy (OK-432-combined adoptive immunotherapy) was significantly decreased compared to the parent MOPC. In vitro experiments showed that MOPC-CPA/R were more resistant (five-fold) to lysis by cultured immune spleen cells than MOPC. Inhibition of the lytic activity of cultured immune spleen cells against MOPC was significantly increased (P less than 0.05) by the addition of unlabeled MOPC compared to unlabeled MOPC-CPA/R. These results suggest that MOPC-CPA/R express weaker antigenicity than MOPC. However, the transfer of immune spleen cells cultured with tumor extract derived from MOPC-CPA/R significantly prolonged the survival of MOPC-CPA/R-inoculated mice. Thus, by repeated cyclophosphamide treatment, tumor cells with low-antigenicity were selected. These tumor cells had lower sensitivity to another chemotherapeutic agent and immunotherapy. Such an immunological response may play an important role in cancer therapy.
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
September 1978,
Journal of the National Cancer Institute,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
October 1976,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
March 1983,
Cancer research,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
August 1989,
Journal of biological response modifiers,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
April 1978,
European journal of biochemistry,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
January 1989,
Cancer investigation,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
March 1977,
Cancer research,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
September 1973,
Journal of immunology (Baltimore, Md. : 1950),
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
April 1980,
Archives of biochemistry and biophysics,
K Satoh, and
N Kan, and
T Okino, and
M Nakanishi, and
K Mise, and
Y Teramura, and
S Yamasaki, and
K Ohgaki, and
T Tobe
January 1985,
Cancer investigation,
